通用中文 | 氯膦酸二钠片 | 通用外文 | Disodium Clodronate |
品牌中文 | 固令 | 品牌外文 | Bonefos |
其他名称 | |||
公司 | 拜耳(Bayer) | 产地 | 芬兰(Finland) |
含量 | 800mg | 包装 | 60片/盒 |
剂型给药 | 储存 | 室温 | |
适用范围 | 适用于治疗恶性肿瘤引起的高钙血症及骨质溶解。 |
通用中文 | 氯膦酸二钠片 |
通用外文 | Disodium Clodronate |
品牌中文 | 固令 |
品牌外文 | Bonefos |
其他名称 | |
公司 | 拜耳(Bayer) |
产地 | 芬兰(Finland) |
含量 | 800mg |
包装 | 60片/盒 |
剂型给药 | |
储存 | 室温 |
适用范围 | 适用于治疗恶性肿瘤引起的高钙血症及骨质溶解。 |
氯膦酸二钠(固令)说明书如下:
【固令药品名称】
通用名称:氯膦酸二钠片
商品名称:固令/Bonefos
英文名称:Disodium Clodronate
【固令成份】
固令主要成份及其化学名称为:氯膦酸二钠四水合物
化学结构式:
分子式:CH2Cl2Na2O6P2·4H2O
分子量:360.92
【固令性状】
固令内容物为白色颗粒状和粉末。
【固令适应症】
氯膦酸二钠胶囊适用于治疗恶性肿瘤引起的高钙血症及骨质溶解。
【固令规格】
800mg
【固令用法用量】
氯膦酸二钠主要经肾脏清除,因此,在氯膦酸二钠治疗过程中一定要维持足够的水份摄入。
氯膦酸二钠胶囊应整粒吞服。
每日剂量1600mg应该单次用药。若日剂量高于1600mg,超过的部分应该分次给药(作为第二剂量),具体如下:
单次日剂量或两次用药的首剂量于早晨空腹以一杯水送服。在随后的1小时内,患者应禁止进食、饮水(白水除外)及口服其它任何药物。
如果一日两次用药,应按上述方法服用个剂量。第二个剂量应在两餐之间服用,时间应安排在进食、饮水(白水除外)或口服其它任何药物2小时之后、1小时之前。
任何情况下不能将氯膦酸盐与含有钙或其它二价阳离子的牛奶、食物或药物同服,因为它们会减少氯膦酸盐的吸收。
●肾功能正常的成年患者
恶性肿瘤所致的高钙血症的治疗
起始剂量应采用高剂量,即每日2400mg或3200mg,依据个体的治疗情况,逐渐减至每日1600mg以维持正常的血清钙水平。
恶性肿瘤所致的骨质溶解的治疗
口服治疗不伴有高钙血症的骨吸收增加时,剂量应个体化。推荐起始剂量为1600mg/天。如果临床需要,可增加剂量,但建议每天不要超过3200mg。
●肾衰患者
氯膦酸盐主要经肾消除。因此,用于肾衰患者时应谨慎;不应连续使用1600mg以上的日剂量。
建议对氯膦酸盐剂量进行如下减低:
肾衰程度肌酐清除率ml/min剂量
轻度50-80每日1600mg(不建议剂量减低)
中度30-50每日1200mg
重度<30每日800mg
【固令不良反应】
氯膦酸盐常见报告的药物反应是腹泻,该反应通常是轻度的,并且在高剂量时更常见。
在可手术治疗的原发性乳腺癌患者中进行的预防骨转移的随机、安慰剂对照的临床试验中,对1079名患者进行了安全性评价,与安慰剂对照组相比,氯膦酸盐组(每日用药剂量1600mg,共2年)发生的不良事件中,仅非重度腹泻明显更常见。在一个由5592位年龄均在75岁以上的患者参加的随机、安慰剂对照研究中,患者每日用药800mg,共用药3年,用来防止由骨质疏松造成的骨折。与安慰剂对照组相比,仅腹泻,恶心和呕吐有所增加。
上市后经验
▲呼吸系统、胸和纵隔异常
阿司匹林过敏哮喘患者发生呼吸功能损害。过敏反应表现为呼吸系统症状。
▲肾脏和泌尿系统异常
肾功能损害(血清肌酐升高和蛋白尿);重度肾脏损伤,尤其是静脉输注高剂量氯膦酸盐后发生。
已有个别的肾衰病例,以及罕见的致死后果的报告,特别是与NSAIDs伴随使用时出现,其中常用的为双氯芬酸。
▲肌肉骨骼与结缔组织异常
已有单个的颌骨坏死病例报告,主要发生在过去曾用氨基-二膦酸盐,如唑来膦酸盐和帕米膦酸盐进行治疗的患者中(又见[注意事项])。在使用氯膦酸二钠的患者中曾有严重的骨骼、关系和/或肌肉疼痛的报告,但这样的报告极少出现,并且在安慰剂随机对照研究中,使用安慰剂和氯膦酸二钠的患者之间无明显差异。使用氯膦酸二钠之后,数日至数月之间出现的症状均有不同。
使用了适宜的MedDRA术语对某一个反应及其症状和相关情况进行描述。
[不良反应]中的MedDRA术语陈述以MedDRA8.1版为基础
【固令禁忌】
氯膦酸二钠胶囊禁用于对固令活性成份或任一辅料过敏的患者,也不得与其它二膦酸盐同时使用。
【固令注意事项】
氯膦酸盐治疗期间必须保持足量的液体摄入。高钙血症或肾衰患者使用氯膦酸盐治疗时,这一点尤其重要。
肾功能衰竭患者使用氯膦酸盐时应谨慎(见[用法用量]中的剂量调整)。
在接受静脉或口服二膦酸盐治疗方案的癌症患者中,已有颌骨坏死报告,通常与拔牙和/或局部感染(包括骨髓炎)有关。这些患者中很多还接受化疗和皮质类固醇治疗。
在伴有危险因素(如癌症,化疗,放疗,皮质类固醇治疗,牙齿卫生状况较差)的患者中使用二膦酸盐治疗前应考虑预防性牙科学,在这些患者中进行二膦酸盐治疗时应该避免有创性牙科操作。
对于在二膦酸盐治疗过程中出现了颌骨坏死的患者,牙科手术会使其进一步恶化。对于需要进行牙科操作的患者,尚无资料可以建议是否停用二膦酸盐治疗可以降低颌骨坏死的风险。
医生应该根据每位患者的利益/风险评估进行临床判断,指导每位患者的用药计划。
【固令孕妇及哺乳期妇女用药】
妊娠
虽然动物实验中,氯膦酸盐可通过胎盘屏障,尚不清楚其是否可以进入胎儿体内。此外,尚不知道氯膦酸盐是否会引起胎儿损害或影响生殖。因此,除非治疗益处明确超过任何风险,否则不应让孕妇使用氯膦酸盐。
哺乳
目前尚未知氯膦酸盐在人体是否经乳汁分泌。因为很多药物可以经乳汁分泌,且因为哺乳时存在由于含有氯膦酸盐而造成临床显著不良反应的可能性,建议氯膦酸盐治疗期间不要进行哺乳。
【固令儿童用药】
尚未确定在儿科患者中的安全性和有效性。
【固令老年用药】
对老年患者没有特殊的剂量建议。临床试验已包括了65岁以上的患者,此年龄组未报告有特别的不良反应。
【固令药物相互作用】
禁止与其它二磷酸盐同时使用。
氯膦酸二钠与非甾体类抗炎止痛剂(NSAIDs)合用,常见的是双氯芬酸,有引起肾功能不全的报告。
由于发生低钙血症的风险增加,氯膦酸盐与氨基糖苷类抗生素同时使用时应特别谨慎。
曾有报告,氯膦酸盐与磷酸雌莫司汀同时使用时,磷酸雌莫司汀的血清浓度增加80%。
氯膦酸盐与二价阳离子可形成难溶复合物。因此,固令不应与含有二价阳离子的食物或药物(如抗酸剂或铁制剂)同时服用。
【固令药物过量】
药物过量时应采取对症治疗。必须保证足够的水量摄入,并监测肾功能和血清钙浓度。
【固令药理毒理】
药效学特性
氯膦酸盐化学上被定义为二磷酸盐,是天然焦磷酸盐的类似物。二磷酸盐对矿化组织,如骨,具有强烈的亲和性。体外研究表明它可抑制磷酸钙沉积,抑制其转化为羟磷灰石,延缓磷灰石晶体聚集成更大的结晶体,并减慢其分解。
但氯膦酸盐主要的作用机制为抑制破坏骨的吸收。氯膦酸二钠抑制几种不同方式的骨吸收。高剂量氯膦酸盐用于成长期大鼠会导致长骨干骺端增宽。
在卵巢切除的大鼠,3mg/kg的低剂量氯膦酸盐每周一次皮下注射即可抑制骨吸收。药理剂量的氯膦酸盐对骨强度减低具有预防作用。氯膦酸盐的药理作用已经不同的骨质疏松临床前动物实验模型证实,其中包括雌激素缺乏所致骨质疏松。氯膦酸盐抑制骨吸收具有剂量依赖性,而对骨矿化或骨质的其他方面无破坏作用。氯膦酸盐亦可抑制实验性肾性骨质营养不良的骨吸收。
组织学、动力学和生化研究明确了氯膦酸盐在人体中有抑制骨吸收的作用。然而,抑制骨吸收的确切机制尚未完全明了。氯膦酸盐可抑制破骨细胞的活性,降低血钙浓度,减少尿中排泌的钙和羟脯氨酸。氯膦酸盐可预防绝经前和绝经后妇女与乳腺癌相关的髋和腰椎骨的丢失。单独应用抑制骨重吸收剂量的氯膦酸盐,未发现会对人体正常的骨矿化产生影响。已观察到可降低乳腺癌和多发性骨髓瘤患者骨折的危险性。氯膦酸盐可减少原发性乳腺癌的骨转移。在可手术治疗的原发性乳腺癌患者中进行的预防骨转移的临床试验中,发现氯膦酸盐治疗与死亡率降低有关。
临床前安全性
●急性毒性
单剂量研究中,口服给药后,小鼠和大鼠的LD50分别为>3600mg/kg和2200mg/kg。
在小鼠和大鼠,急性毒性的临床征象包括运动活动减少、惊厥、意识丧失及呼吸困难。在小型猪,240mg/kg静脉给药剂量在两次或三次输注后可产生毒性。
●全身耐受性
进行了大鼠和小型猪为期2周至12个月不等的多剂量毒理学研究。大鼠口服100-480mg/kg。小型猪每天口服80mg/kg,未发现与药物有关的死亡。
毒性研究发现,氯膦酸盐会影响下述器官(括号内是观察到的变化):骨骼(与氯膦酸盐药理作用有关的硬化)、胃肠道(刺激)、血液(淋巴细胞减少、对止血的影响)、肾脏(肾小管扩张、蛋白尿)、及肝脏(血清转氨酶水平升高)。
●生殖毒性
动物研究中,氯膦酸盐没有损伤胎儿,但高剂量可使雄性动物的生育力降低。对新生大鼠皮下注射氯膦酸盐一个月后,发现了类似于骨硬化病的骨骼改变,该改变与氯膦酸盐的药理作用有关。
●潜在的遗传毒性和致癌性
氯膦酸盐未表现出潜在的遗传毒性。对大鼠和小鼠的研究中没有观察到致癌作用。
【固令药代动力学】
●吸收
与其它二膦酸盐相同,氯膦酸盐的胃肠道吸收很低,约为2%。氯膦酸盐吸收迅速,单次给药后,于30分钟内即可达到血清峰浓度。由于氯膦酸盐对钙和其它二价阳离子有强烈的亲和性,所以当氯膦酸盐与饮食或含有二价阳离子的药物同时服用时,其吸收可忽略不计。在一项研究中,以在早餐前2小时服用氯膦酸盐作为参比治疗,结果表明1小时或0.5小时的给药-早餐间隔使氯膦酸盐的生物利用度降低,但其差异没有统计学意义(相对生物利用度分别为91%和69%)。此外,氯膦酸盐的生物利用度在个体间和个体内都存在较大变异。尽管氯膦酸盐吸收的个体内差异很大,长期治疗时氯膦酸盐的暴露程度仍保持不变。
●分布与清除
氯膦酸盐的血浆蛋白结合率低,分布容积为20-50L。氯膦酸盐的血清消除表现为两个显著不同的相:分布相半衰期约为2小时,而消除相却因氯膦酸盐与骨紧密结合而非常慢。氯膦酸盐主要经肾消除。在给药后几天内,吸收的氯膦酸盐约有80%出现在尿中。与骨结合的部分(约占吸收量的20%)排泄更慢,肾清除率约为血浆清除率的75%。
●患者体内的特性
因为氯膦酸盐影响骨骼,氯膦酸盐的血浆或血液浓度与治疗活性或药物不良反应之间并无明确的关系。除能够使氯膦酸盐肾清除降低的肾功能不全外,药代动力学过程不受与年龄、药物代谢或其他病理状态有关的任何已知因素的影响。
【固令贮藏】
不要贮藏于25℃以上。勿使儿童接触。
【固令包装】
PVC/铝箔水泡眼包装,10粒/盒;30粒/盒;60粒/盒;100粒/盒。
【固令有效期】
60个月
【固令生产企业】
企业名称:BayerOy
国内分装企业:拜耳医药保健有限公司广州分公司
Bonefos® 800mg Tablets
(sodium clodronate)
Your medicine is known by the above name, but
will be referred to as
Bonefos Tablets throughout this leaflet.
Patient Information Leaflet
Read all of this leaflet carefully before you
start taking this medicine
because it contains important information for
you.
− Keep this leaflet. You may need to read it
again.
− If you have any further questions, ask your
doctor or pharmacist.
− This medicine has been prescribed for you
only. Do not pass it on to
others. It may harm them, even if their signs
of illness are the same as
yours.
− If you get any side effects, talk to your
doctor or pharmacist. This
includes any possible side effects not listed
in this leaflet. See section 4.
What is in this leaflet
1) What Bonefos Tablets are and what they are
used for
2) What you need to know before you take
Bonefos Tablets
3) How to take Bonefos Tablets
4) Possible side effects
5) How to store Bonefos Tablets
6) Contents of the pack and other information
1) What Bonefos Tablets are and what they are
used for
Bonefos Tablets contain sodium clodronate
which belongs to a group of
medicines called bisphosphonates. These
medicines help prevent the loss
of calcium from bones.
►
a drug called estramustine which is used to
treat cancer.
Do not take any other medicines by mouth for 2
hours before and 1 hour
after each dose of Bonefos Tablets.
Bonefos Tablets with food and drink
It is important that you take your tablets on
an empty stomach (otherwise
your body will not absorb the drug properly).
Except for plain water, do not eat or drink
for 2 hours before and 1 hour
after each dose. It is particularly important
to avoid drinking milk in this
period.
You can drink water whenever you like.
Pregnancy and breastfeeding
Bonefos Tablets are not normally given to
people during pregnancy. If you
are pregnant, think you may be pregnant or are
planning to have a baby,
ask your doctor or pharmacist for advice
before taking this medicine.
Do not breastfeed while you are taking Bonefos
Tablets.
Driving and using machines
Bonefos Tablets have no known effect on your
ability to drive or use
machines.
3) How to take Bonefos Tablets
You need to take plenty of fluids (such as
water) before, during and
after your treatment.
Always take this medicine exactly as your
doctor or pharmacist has told
you. Check with your doctor or pharmacist if
you are not sure.
Bonefos Tablets are used to help manage bone
diseases, particularly those
associated with cancer. Bonefos Tablets also
help maintain normal levels of
calcium in your blood.
The tablets should be swallowed with plain
water. Tablets may be divided
into two halves to help with swallowing, but
the two halves must be taken at
the same time.
2) What you need to know before you take
Bonefos Tablets
Do not crush or dissolve the tablets before
you take them. Never take
them with milk because it reduces the amount
of drug that your body can
absorb.
Do not take Bonefos Tablets if:
► you have very poor kidney function
► you are allergic to sodium clodronate, or to
any of the other ingredients
of this medicine (listed in section 6).
► you are already taking another similar
medicine.
â Tell your doctor if any of these apply to
you and do not take Bonefos
Tablets.
Warnings and precautions
Talk to your doctor or pharmacist before
taking Bonefos tablets.
Your doctor will take special care if:
► you have problems with your kidneys
► you have (or have had) pain, swelling or
numbness of the jaw or a
“heavy jaw feeling” or loosening of a tooth.
â Tell your doctor before you take Bonefos
Tablets, if any of these apply
to you.
If you are having dental treatment or will
undergo dental surgery, tell your
dentist that you are being treated with a
bisphosphonate. Certain types of
dental treatment are not recommended while
taking bisphosphonates.
The daily dosage of Bonefos Tablets varies. In
most cases the dose is
between 1600mg (2 tablets) and 3200mg (4
tablets) per day. If you have
problems with your kidneys then the daily
dosage may be reduced.
If you
have been prescribed a single daily dose of
Bonefos Tablets, it
should be taken (preferably in the morning) on
an empty stomach with a
glass of plain water. After using Bonefos
Tablets, you should not eat,
drink (other than plain water) or take any
other medicines by mouth
for 1 hour.
If you have been prescribed a twice daily
dose, the first dose should be
taken as recommended above. The second dose
should be taken between
meals, more than 2 hours after and 1 hour
before eating, drinking
(other than plain water), or taking any other
medicines by mouth.
If you take more Bonefos Tablets than you
should
â Get medical help immediately and drink
plenty of water. If possible,
take your tablets with you to show the doctor.
Your doctor may want to
check the amount of calcium in your blood and
how well your kidneys
and liver are working.
Other medicines and Bonefos Tablets
Tell your doctor if you are taking, have
recently taken or might take any
other medicines.
If you forget to take Bonefos Tablets
Do not take the missed dose, just take your
next dose at the usual time.
Tell your doctor if you are taking:
► non-steroidal anti-inflammatory drugs to
relieve pain (e.g. ibuprofen
or diclofenac)
► antibiotics
► antacids or mineral supplements
4) Possible side effects
Like all medicines, this medicine can cause
side effects, although not
everybody gets them. The following side effects
have been observed during
treatment with Bonefos Tablets.
If you experience any of these serious side effects, seek immediate
medical attention:
► difficulty breathing
► allergic skin reactions such as a rash,
redness or itching
► numbness and tingling sensations around the
mouth and/or in the
fingers and toes, muscle cramps or spasms (in
the back, hands and/or
feet) or fits
► kidney problems which can be experienced as
feeling generally unwell,
a reduced appetite and you may observe foamy
urine
► severe kidney damage which may include
symptoms such as weakness
or tiredness, change in frequency of urination
and swelling of the face,
arms, legs and abdomen. These problems are
more common when
taking some types of anti-inflammatory drug
(most often diclofenac) at
the same time as Bonefos Tablets
► pain, swelling or numbness of the jaw, a
“heavy jaw feeling” or
loosening of a tooth, especially if you who
have been treated in the past
with bisphosphonates such as zoledronate and
pamidronate
► severe bone, joint and/or muscle pain that
can start days to several
months after starting treatment with Bonefos
Tablets.
► talk to your doctor if you have ear pain,
discharge from the ear, and/or
an ear infection. These could be signs of bone
damage in the ear
(osteonecrosis of the external auditory canal)
which could occur very
rarely.
Unusual fracture of the thigh bone
particularly in patients on long-term
treatment for osteoporosis may occur rarely.
Contact your doctor if you
experience pain, weakness or discomfort in
your thigh, hip or groin as this
may be an early indication of a possible
fracture of the thigh bone.
The following side effects are presented by
how often they may occur:
Common side effects
(may affect up to 1 in 10 people)
► low calcium levels in the blood without any
symptoms (asymptomatic
hypocalcaemia) or small increases in the
levels of liver enzymes, which
can be detected by blood tests
► diarrhoea
► feeling sick or being sick
Rare side effects
(may affect up to 1 in 1,000 people)
► low calcium levels in the blood with
symptoms (symptomatic
hypocalcaemia) which may include numbness and
tingling sensations
around the mouth and/or in the fingers and
toes, muscle cramps or
spasms (in the back, hands and/or feet) or,
less frequently, fits
► increased blood levels of a hormone
(parathyroid hormone) or certain
enzymes (alkaline phosphatase) which can be
detected by blood tests
► allergic skin reaction such as a rash,
redness or itching
► breathing difficulties (bronchospasm) – if
you have any difficulties
breathing seek immediate medical attention.
► Unusual fracture of the thigh bone
(particularly in patients on long-term
treatment for osteoporosis) – contact your
doctor if you experience
pain, weakness or discomfort in your thigh,
hip or groin
Other side effects (frequency unknown)
► breathing problems in patients with a
condition called aspirin-sensitive
asthma
► allergic reaction causing difficulty
breathing – if you have any difficulty
breathing seek immediate medical attention
► kidney problems which may include severe
kidney damage and in rare
cases fatal kidney failure have been reported.
These problems are
more common when taking some types of
anti-inflammatory drug (most
often diclofenac) at the same time as Bonefos
Tablets
► dead tissue in the jaw bone (osteonecrosis
of the jaw) which is mainly
seen in patients who have been treated in the
past with
bisphosphonates such as zoledronate and
pamidronate. Symptoms
include pain, swelling or numbness of the jaw,
a “heavy jaw feeling” or
loosening of a tooth
► severe bone, joint and/or muscle pain that
can start days to several
months after starting treatment with Bonefos
Tablets. However, these
symptoms may also be linked to the reason you
are taking Bonefos
Tablets.
► Swelling and irritation of the uvea (the
middle layer of the eye) has been
observed with Bonefos Tablets. Swelling or
infection of the conjunctiva
(the membrane lining of the eyelids) has been
reported in one patient
who received Bonefos Tablets and another
biphosphonate at the same
time. To date, swelling and irritation of the
episclera (a thin layer of
tissue covering the sclera, the white outer
wall of the eye) and the
sclera, which has been reported with other
biphosphonates, have not
been reported with Bonefos Tablets.
â Tell your doctor if any side effect gets
serious, or if you get any
effects not listed in this leaflet.
Reporting of side effects
If you get any side effects, talk to your
doctor, pharmacist or nurse. This
includes any possible side effects not listed
in this leaflet. You can also
report side effects directly via the Yellow
Card Scheme at:
www.mhra.gov.uk/yellowcard. By reporting side
effects, you can help
provide more information on the safety of this
medicine.
5) How to store Bonefos Tablets
Keep out of the sight and reach of children.
Do not use after the expiry date which is
stated on the carton and on
each blister strip of tablets. The expiry date
refers to the last day of that
month.
Do not store above 30°C.
Medicines should not be disposed of via
wastewater or household
waste. Ask your pharmacist how to dispose of
medicines no longer
required. These measures will help to protect
the environment.
If your doctor tells you to stop taking the
tablets, please take them back
to the pharmacist for safe disposal. Only keep
the tablets if your doctor
tells you to.
6) Contents of the pack and other information
What Bonefos Tablets contains
The active substance is sodium clodronate.
Each tablet contains 800mg of sodium
clodronate (as the tetrahydrate).
The tablets also contain croscarmellose
sodium, magnesium stearate,
silicified microcrystalline cellulose and
stearic acid.
The tablet coating is made from Opadry
Y-1-7000, which contains
hypromellose, titanium dioxide E171 and
macrogol 400.
What Bonefos Tablets looks like and contents
of the pack
Pale white, oval-shaped, film-coated tablets
printed with ‘L’ breakline ‘134’
on one side and plain on the other side.
Bonefos Tablets are available in blister
strips of 60 in a carton.
PL 10383/1871
Bonefos 800mg Tablets
POM
Who makes and repackages your medicine?
Your medicine is manufactured Bayer Schering
Pharma Oy Pansiontie 47
20210 Turku, Finland. Procured from within the
EU and repackaged by
Product Licence Holder: Primecrown Ltd, 4/5
Northolt Trading Estate,
Belvue Road, Northolt, Middlesex, UB5 5QS.
Leaflet date: 13.09.2016
Bonefos is a registered trademark of Bayer Oy,
Finland.